11月3日，特宝生物盘中上涨2.03%，截至10:43，报74.49元/股，成交1.16亿元，换手率0.38%，总市值 304.06亿元。 资金流向方面，主力资金净流入192.34万元，特大单买入144.97万元，占比1.25%，卖出264.18万元，占 比2.28%；大单买入2369.20万元，占比20.44%，卖出2057.64万元，占比17.75%。 特宝生物今年以来股价涨2.39%，近5个交易日涨4.92%，近20日跌9.19%，近60日跌17.90%。 截至9月30日，特宝生物股东户数8608.00，较上期增加2.00%；人均流通股47258股，较上期减少 1.96%。2025年1月-9月，特宝生物实现营业收入24.80亿元，同比增长26.85%；归母净利润6.66亿元，同 比增长20.21%。 分红方面，特宝生物A股上市后累计派现5.77亿元。近三年，累计派现5.06亿元。 资料显示，厦门特宝生物工程股份有限公司位于福建省厦门市海沧新阳工业区翁角路330号，成立日期 1996年8月7日，上市日期2020年1月17日，公司主营业务涉及从事重组蛋白质及其长效修饰药物研发、 生产及销售。主营业务收入构成 ...

Core Viewpoint - The stock of TEBIO has shown a slight increase of 2.03% on October 29, with a current price of 72.45 CNY per share, despite a year-to-date decline of 0.41% and a more significant drop of 6.29% over the past five trading days [1] Financial Performance - For the period from January to September 2025, TEBIO achieved a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, reflecting a growth of 20.21% compared to the previous year [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

Core Viewpoint - The stock of TEBIO has experienced a decline, with a current price of 71.16 CNY per share, reflecting a year-to-date drop of 2.19% and a significant decrease over the past five trading days of 8.36% [1] Financial Performance - For the period from January to September 2025, TEBIO reported a revenue of 2.48 billion CNY, representing a year-on-year growth of 26.85%. The net profit attributable to shareholders was 666 million CNY, showing a year-on-year increase of 20.21% [2] Shareholder Information - As of September 30, 2025, TEBIO had 8,608 shareholders, an increase of 2% from the previous period. The average number of circulating shares per shareholder decreased by 1.96% to 47,258 shares [2] Dividend Distribution - TEBIO has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the seventh-largest circulating shareholder is E Fund's SSE STAR 50 ETF, holding 5.88 million shares, a decrease of 856,700 shares from the previous period. The eighth-largest shareholder is Huaxia's SSE STAR 50 Component ETF, holding 5.73 million shares, down by 3.22 million shares [3]

10月17日，特宝生物跌1.52%，截至发稿，报77.65元/股，成交1.19亿元，换手率0.37%，总市值315.88 亿元。特宝生物股价已经连续4天下跌，区间累计跌幅7.44%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，厦门特宝生物工程股份有限公司位于福建省厦门市海沧新阳工业区翁角路330号，成立日期 1996年8月7日，上市日期2020年1月17日，公司主营业务涉及从事重组蛋白质及其长效修饰药物研发、 生产及销售。主营业务收入构成为：抗病毒用药86.85%，血液/肿瘤用药12.87%，其他(补充)0.27%。 责任编辑：小浪快报 从基金十大重仓股角度 华泰柏瑞量化创盈混合A（010303）基金经理为笪篁。 截至发稿，笪篁累计任职时间5年161天，现任基金资产总规模13.15亿元，任职期间最佳基金回报 62.41%， 任职期间最差基金回报-1.1%。 数据显示，华泰柏瑞基金旗下1只基金重仓特宝生物。华泰柏瑞量化创盈混合A（010303）二季度持有 股 ...

Core Viewpoint - The stock of TEBIO experienced a decline of 2.06% on October 16, 2023, with a trading volume of 1.40 billion yuan and a market capitalization of 31.974 billion yuan [1] Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96%, and a net profit attributable to shareholders of 428 million yuan, which is a 40.60% increase compared to the previous year [2] Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period, with an average of 48,204 circulating shares per shareholder, down by 11.51% [2] - The stock's performance shows an 8.04% increase year-to-date, but a decline of 3.44% over the last five trading days and 3.99% over the last twenty days [1] Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders included the Huaxia SSE STAR 50 ETF, which increased its holdings by 837,500 shares, and the E Fund SSE STAR 50 ETF, which added 189,900 shares [3]

Core Viewpoint - The stock of TEBIO experienced a decline of 2.00% on October 14, with a current price of 82.21 CNY per share and a market capitalization of 33.443 billion CNY. The company has seen a year-to-date stock price increase of 13.00% but has faced a slight decline in the recent trading periods [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%. The net profit attributable to shareholders was 428 million CNY, showing a year-on-year increase of 40.60% [2]. - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period. The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. - The major shareholders include ETFs such as 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, which have increased their holdings [3]. Company Overview - TEBIO, established on August 7, 1996, and listed on January 17, 2020, is based in Xiamen, Fujian Province. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with a revenue composition of 86.85% from antiviral drugs and 12.87% from blood/cancer drugs [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1].

Core Viewpoint - The stock of TEBIO has shown a positive trend with a year-to-date increase of 15.02% and a recent rise of 5.63% over the last five trading days, indicating strong market interest and performance [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion yuan, representing a year-on-year growth of 26.96% [2]. - The net profit attributable to shareholders for the same period was 428 million yuan, reflecting a year-on-year increase of 40.60% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 8,439, up by 13 compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. Dividend Distribution - TEBIO has distributed a total of 577 million yuan in dividends since its A-share listing, with 506 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, 2025, major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with both increasing their holdings [3].

Company Overview - Teabo Bioengineering Co., Ltd. is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs [1][2] - The main business revenue composition includes antiviral drugs (86.85%), blood/cancer drugs (12.87%), and other (supplement) (0.27%) [1] Financial Performance - For the first half of 2025, Teabo Bio achieved operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%, and a net profit attributable to shareholders of 428 million yuan, a year-on-year increase of 40.60% [2] - Since its A-share listing, Teabo Bio has distributed a total of 577 million yuan in dividends, with 506 million yuan distributed over the past three years [2] Stock Performance - As of September 25, Teabo Bio's stock price increased by 2.08%, reaching 83.08 yuan per share, with a total market capitalization of 33.797 billion yuan [1] - Year-to-date, the stock price has risen by 14.20%, with a 4.46% increase over the last five trading days and a 14.94% increase over the last 60 days [1] Shareholder Information - As of June 30, the number of shareholders for Teabo Bio was 8,439, an increase of 13.00% from the previous period, while the average circulating shares per person decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation 50 ETF and E Fund SSE Sci-Tech Innovation 50 ETF increased their holdings [2]